bafetinib

bafetinib

A Bcr-Abl/Lyn dual tyrosine kinase inhibitor, which may suppress the growth of CLL cells by inhibition of Lyn kinase. Imatinib-resistant CLL cells are associated with an overexpression of Lyn kinase, a factor in the proliferation and survival of B-CLL cells. It has no effect on c-Src kinase activity, and may be less toxic than other broad Src family kinase inhibitors. Bafetinib has shown therapeutic potential in phase-II trials in patients with relapsed or refractory B-cell chronic lymphocytic leukaemia.